Tankyrase inhibitors attenuate WNT/ß-catenin signaling and inhibit growth of hepatocellular carcinoma cells

Oncotarget

Volumn 6, Issue 28, 2015, Pages 25390-25401

  Ma, Li ^a   Wang, Xiaolin ^a,c   Jia, Tao ^b   Wei, Wei ^a   Chua, Mei Sze ^a   So, Samuel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WUHAN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; catenin TCF complexes; tankyrase inhibitors; targeted therapy; WNT catenin signaling

Indexed keywords

7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; BETA CATENIN; MESSENGER RNA; SMALL INTERFERING RNA; TANKYRASE; TANKYRASE 1; TANKYRASE 2; TANKYRASE INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN; WXL 8; AXIN; AXIN1 PROTEIN, HUMAN; AXIN2 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TNKS PROTEIN, HUMAN; TNKS2 PROTEIN, HUMAN; WNT3A PROTEIN; WNT3A PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; GENE SILENCING; HEP40 CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HUH7 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TNKS1 GENE; TNKS2 GENE; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEP-G2 CELL LINE; LIVER NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROTEIN STABILITY; REPORTER GENE; RNA INTERFERENCE; SCID MOUSE; TIME FACTOR; TUMOR VOLUME;

ANIMALS; AXIN PROTEIN; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEP G2 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LIVER NEOPLASMS; MALE; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROTEIN STABILITY; RNA INTERFERENCE; TANKYRASES; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; WNT SIGNALING PATHWAY; WNT3A PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944455959     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4455     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Institute NC. http://seer.cancer.gov/statfacts/html/livibd .html. Last accessed: 2015 Jan 23.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142:1264-1273. e1261.
4. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245-1255.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378-390.
6. European Association for Study of L, European Organisation for R and Treatment of C: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012; 48:599-641.
7. Villanueva A, Llovet JM. Liver cancer in 2013: Mutational landscape of HCC-the end of the beginning. Nat Rev Clin Oncol. 2014; 11:73-74.
8. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127:469-480.
9. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2012; 18:4997-5007.
10. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008; 8:387-398.
11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science. 1998; 281:1509-1512.
12. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999; 398:422-426.
13. Lee HH, Uen YH, Tian YF, Sun CS, Sheu MJ, Kuo HT, Koay LB, Lin CY, Tzeng CC, Cheng CJ, Tang LY, Tsai SL, Wang AH. Wnt-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery. Cancer Epidemiol Biomarkers Prev. 2009; 18:1562-1569.
14. Wei W, Chua MS, Grepper S, So SK. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer. 2009; 8:76.
15. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, Kew MC, Trepo C, Wands JR. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology. 2004; 127:1110-1122.
16. Tung EK, Wong BY, Yau TO, Ng IO. Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. PLoS One. 2012; 7:e36565.
17. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014; 13:513-532.
18. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009; 461:614-620.
19. Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov. 2012; 11:923-936.
20. Lehtio L, Chi NW, Krauss S. Tankyrases as drug targets. FEBS J. 2013; 280:3576-3593.
21. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, Gradl D, Voronkov A, von Kries JP, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012; 72:2822-2832.
22. Bao R, Christova T, Song S, Angers S, Yan X, Attisano L. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS One. 2012; 7:e48670.
23. Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ. Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer. 2013; 13:211.
24. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A. 1998; 95:8847-8851.
25. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ, Boman BM. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 2001; 61:8664-8667.
26. Ma L, Wei W, Chua MS, So S. WNT/ß-catenin pathway activation in hepatocellular carcinoma: a clinical perspective. Gastrointestinal Cancer: Targets and Therapy. 2014; 4:49-63.
27. Polakis P. Drugging Wnt signalling in cancer. EMBO J. 2012; 31:2737-2746.
28. Shultz MD, Cheung AK, Kirby CA, Firestone B, Fan J, Chen CH, Chen Z, Chin DN, Dipietro L, Fazal A, Feng Y, Fortin PD, Gould T, et al. Identification of NVP-TNKS6: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J Med Chem. 2013; 56:6495-6511.
29. Reguera G, McCarthy KD, Mehta T, Nicoll JS, Tuominen MT, Lovley DR. Extracellular electron transfer via microbial nanowires. Nature. 2005; 435:1098-1101.
30. Sun CK, Chua MS, He J, So SK. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-beta2. Neoplasia. 2011; 13:735-747.